BioXcel Therapeutics (BTAI) Non Operating Income (2022 - 2026)

BioXcel Therapeutics' Non Operating Income history runs 5 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• In Q1 2026, Non Operating Income fell 76.84% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at -$8.6 million (down 132.05% YoY), while the FY2025 annual figure was -$3.5 million, down 117.44% from the prior year.
• Non Operating Income was $1.5 million for Q1 2026 at BioXcel Therapeutics, down from $1.8 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $12.0 million in Q2 2024 to a low of -$12.5 million in Q3 2025.
• Historically, Non Operating Income has averaged $1.2 million across 5 years, with a median of $537000.0 in 2023.
• The sharpest annual moves came in 2024 and 2025: Non Operating Income surged 96440.0% in 2024, then sank 360.45% in 2025.
• A 5-year view of Non Operating Income shows it stood at -$480000.0 in 2022, then soared by 122.5% to $108000.0 in 2023, then jumped by 2953.7% to $3.3 million in 2024, then tumbled by 45.06% to $1.8 million in 2025, then retreated by 16.17% to $1.5 million in 2026.
• The last three Non Operating Income figures came in at $1.5 million (Q1 2026), $1.8 million (Q4 2025), and -$12.5 million (Q3 2025), per Business Quant data.